The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- No Remarkable Increases in Infections in Disaster-hit Areas: NIID
April 25, 2011
- Japan Should Join PIC/S to Harmonize Its GMP with Global Standards: Dr Sakurai of PMDA
April 25, 2011
- Teijin Pharma Announces New Global Partners for TMX-67
April 25, 2011
- DSP's Pharmacist Employees Volunteer to Assist in Disaster Area
April 25, 2011
- Nomura Securities Predicts Plummeting Profitability for Daiichi Sankyo's Pravastatin
April 25, 2011
- PMDA to Provide Consultation Services for Wider Range of OTC Drugs
April 25, 2011
- Yakult Licenses Resminostat from 4SC of Germany
April 25, 2011
- Korosho Publishes Medical Societies' Views on Switch OTC Drug Candidates
April 25, 2011
- Taiho Licenses Antiemetic Combination Drug from Helsinn
April 25, 2011
- Takeda, Samyang to Collaborate for RNAi DDS Tech
April 25, 2011
- New ARB EDARBI Launched in the US: Takeda
April 25, 2011
- Takeda Starts PIII Trial of AMG479 in Metastatic Pancreatic Cancer
April 25, 2011
- Tsumura Establishes Licorice Cultivation Methods in China
April 25, 2011
- OPF to Codevelop DIABECELL with LCT for Islet Replacement Therapy
April 25, 2011
- Mochida to Resume Full Production of Oral Drugs by Late June
April 25, 2011
- CytRx to Develop TMRC's Tamibarotene for NSCLC in North America
April 25, 2011
- Mohrus Tape Production Partially Recovers at Hisamitsu Factory
April 25, 2011
- Shipment of Hundreds of Drug Brands Affected by Quake
April 25, 2011
- NEW PRODUCTS
April 25, 2011
- Bayer Yakuhin Aims at Sales of Over ¥200 Bil. in 2-3 Years
April 25, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…